Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MPDL3280A (Atezolizumab) in Solid Tumors Post-Imaging
NCT02478099Phase 2Active, not recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Feb 2016
- Primary completion
- Sep 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab in solid tumor, sponsored by University Medical Center Groningen. Primary endpoint: Objective Response Rate at 2 years. Started Feb 2016; status: active, not recruiting.
02
Drugs
atezolizumab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02478099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02478099.